 |
|
|
| |
A Phase II, open-label trial in treatment-naïve, HIV-1-infected patients who received DRV/r as induction monotherapy
|
| |
| |
Reported by Jules Levin
EACS Nov 13 2009, Cologne, Germany
Patricia Patterson,1 Alejandro Krolewiecki,1 Frank Tomaka,2 Sabrina Spinosa-Guzman,3 Diego Miralles4 and Pedro Cahn1
1Fundacion Huesped, Buenos Aires, Argentina;
2Tibotec Inc, Yardley, PA, USA; 3Tibotec BVBA, Mechelen, Belgium; 4PRD West Coast Research Center, San Diego, CA, USA
1. Squires et al, 5th IAS 2009. Abstract TUAB106-LB; Ripamonti et al, 12th EACS 2009. Abstract PS4/1
*The following polymorphisms were allowed as they have no known effect on DRV susceptibility: I13V, K20I/M/R, M36I/V, D60E, I62V, L63P, A71T/V, V77I and I93L
|
| |
|
|
|
|
|
